Another manuscript from our group this week with the first structures of the human P2X7 receptor facilitating development of a novel scaffold for P2X7R antagonists:
urldefense.com/v3/__https:/...
@pacificnwcryoem.bsky.social
@ohsunews.bsky.social
@ohsubrain.bsky.social
urldefense.com/v3/__https:/...
@pacificnwcryoem.bsky.social
@ohsunews.bsky.social
@ohsubrain.bsky.social
September 15, 2025 at 6:11 PM
Another manuscript from our group this week with the first structures of the human P2X7 receptor facilitating development of a novel scaffold for P2X7R antagonists:
urldefense.com/v3/__https:/...
@pacificnwcryoem.bsky.social
@ohsunews.bsky.social
@ohsubrain.bsky.social
urldefense.com/v3/__https:/...
@pacificnwcryoem.bsky.social
@ohsunews.bsky.social
@ohsubrain.bsky.social
The P2X7R/NLRP3 inflammasome axis suppresses tendon-to-bone interface regeneration through inflammatory and metabolic cross-talk
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
April 25, 2025 at 6:13 PM
The P2X7R/NLRP3 inflammasome axis suppresses tendon-to-bone interface regeneration through inflammatory and metabolic cross-talk
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
A brain-penetrant P2X7R antagonist mitigates Alzheimer’s disease pathology www.biorxiv.org/content/10.64898/2026.04.06.716621v1 #cryoem
April 12, 2026 at 8:48 PM
A brain-penetrant P2X7R antagonist mitigates Alzheimer’s disease pathology www.biorxiv.org/content/10.64898/2026.04.06.716621v1 #cryoem
NEW in @plosone.org promising #glioblastoma therapeutic target. Dr Matthew Drill & team
@masturamonif.bsky.social @monashuniversity.bsky.social
reveal an alternative pathway with selective targeting to complement existing treatments and/or offer new treatment doi.org/10.1371/jour... #neuroscience
@masturamonif.bsky.social @monashuniversity.bsky.social
reveal an alternative pathway with selective targeting to complement existing treatments and/or offer new treatment doi.org/10.1371/jour... #neuroscience
Purinergic P2X receptor 7 (P2X7R) inhibition induced cytotoxicity in glioblastoma
Glioblastoma is the most common and aggressive form of primary brain cancer with a median survival of 15 months from diagnosis. The purinergic receptor P2X7 (P2X7R) is a regulator of several cell sign...
doi.org
September 19, 2025 at 4:54 AM
NEW in @plosone.org promising #glioblastoma therapeutic target. Dr Matthew Drill & team
@masturamonif.bsky.social @monashuniversity.bsky.social
reveal an alternative pathway with selective targeting to complement existing treatments and/or offer new treatment doi.org/10.1371/jour... #neuroscience
@masturamonif.bsky.social @monashuniversity.bsky.social
reveal an alternative pathway with selective targeting to complement existing treatments and/or offer new treatment doi.org/10.1371/jour... #neuroscience
P2X7 antagonists showing promise for suppression of neuroinflammatory responses. Our paper out in Brain now. #ionchannels
academic.oup.com/brain/advanc...
academic.oup.com/brain/advanc...
P2X7R-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics
Cowley et al. show that CNS-penetrant, selective P2X7 receptor antagonists reduce the release of pro-inflammatory cytokines from human microglia and brain
academic.oup.com
February 23, 2026 at 8:56 AM
P2X7 antagonists showing promise for suppression of neuroinflammatory responses. Our paper out in Brain now. #ionchannels
academic.oup.com/brain/advanc...
academic.oup.com/brain/advanc...
Targeting P2X7R in synovial fibroblasts offers a promising strategy for treating refractory rheumatoid arthritis
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
May 22, 2026 at 10:26 PM
Targeting P2X7R in synovial fibroblasts offers a promising strategy for treating refractory rheumatoid arthritis
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Have you seen the new evidence that allosteric modulation of P2X7R can be governed by long-range influences from extracellular domains, as shown in Yu et al. in Neuropharmacology bit.ly/4aJP4BB #PapersoftheWeek #EditorsPick
December 15, 2025 at 1:00 PM
Have you seen the new evidence that allosteric modulation of P2X7R can be governed by long-range influences from extracellular domains, as shown in Yu et al. in Neuropharmacology bit.ly/4aJP4BB #PapersoftheWeek #EditorsPick
RRIDs were included in this in bioRxiv paper. RRIDs improve reproducibility in scientific research. #RRID #STMpublishing #OpenScience
A brain-penetrant P2X7R antagonist mitigates Alzheimer’s disease pathology
Read the full paper: A brain-penetrant P2X7R antagonist mitigates Alzheimer’s disease pathology
doi.org
April 17, 2026 at 7:05 AM
RRIDs were included in this in bioRxiv paper. RRIDs improve reproducibility in scientific research. #RRID #STMpublishing #OpenScience
Can one immune receptor influence multiple #SkinDiseases?
This review explores how #P2X7R regulates #inflammation, #WoundHealing, and #TumorBiology, highlighting its promise as a precision therapeutic target. #Dermatitis #Fibroblasts
#OpenAccess: doi.org/10.1016/j.ge...
This review explores how #P2X7R regulates #inflammation, #WoundHealing, and #TumorBiology, highlighting its promise as a precision therapeutic target. #Dermatitis #Fibroblasts
#OpenAccess: doi.org/10.1016/j.ge...
July 10, 2026 at 10:31 AM
Can one immune receptor influence multiple #SkinDiseases?
This review explores how #P2X7R regulates #inflammation, #WoundHealing, and #TumorBiology, highlighting its promise as a precision therapeutic target. #Dermatitis #Fibroblasts
#OpenAccess: doi.org/10.1016/j.ge...
This review explores how #P2X7R regulates #inflammation, #WoundHealing, and #TumorBiology, highlighting its promise as a precision therapeutic target. #Dermatitis #Fibroblasts
#OpenAccess: doi.org/10.1016/j.ge...
pivotal regulator of these neuroimmune responses. This narrative review synthesizes the literature on P2X7R-mediated neuroinflammation and glial modulation in migraine. (🧵 2/9)
May 21, 2026 at 10:43 AM
pivotal regulator of these neuroimmune responses. This narrative review synthesizes the literature on P2X7R-mediated neuroinflammation and glial modulation in migraine. (🧵 2/9)
The authors included RRIDs in their paper! We value the author's support of reproducibility. #OpenScience #methodsmatter #ReproducibleResearch
Purα overexpression mitigates neonatal hypoxic-ischemic brain damage by inhibiting neuronal pyroptosis via the P2X7R/NLRP3/Caspase-1 pathway
doi.org
January 28, 2026 at 11:01 PM
The authors included RRIDs in their paper! We value the author's support of reproducibility. #OpenScience #methodsmatter #ReproducibleResearch
A paper using RRID:CVCL_0140 (from ATCC) was just published in Phytomedicine see "Embelin improves alcoholic steatohepatitis in alcohol-associated liver disease via ATF6-mediated P2X7r-NLRP3 signaling pathway". Thank you for making your methods matter! #methodsmatter #OpenScience
doi.org
April 3, 2025 at 7:01 AM
A paper using RRID:CVCL_0140 (from ATCC) was just published in Phytomedicine see "Embelin improves alcoholic steatohepatitis in alcohol-associated liver disease via ATF6-mediated P2X7r-NLRP3 signaling pathway". Thank you for making your methods matter! #methodsmatter #OpenScience
upregulation (P ＜ 0.05).
CONCLUSIONS: QGJY alleviates migraine and inhibits central sensitization in rats, potentially by downregulating P2X7R expression, concomitantly suppressing autophagy, attenuating microglial activation, and reducing pro-inflammatory cytokine release. (🧵 8/8)
CONCLUSIONS: QGJY alleviates migraine and inhibits central sensitization in rats, potentially by downregulating P2X7R expression, concomitantly suppressing autophagy, attenuating microglial activation, and reducing pro-inflammatory cytokine release. (🧵 8/8)
February 25, 2026 at 3:51 PM
upregulation (P ＜ 0.05).
CONCLUSIONS: QGJY alleviates migraine and inhibits central sensitization in rats, potentially by downregulating P2X7R expression, concomitantly suppressing autophagy, attenuating microglial activation, and reducing pro-inflammatory cytokine release. (🧵 8/8)
CONCLUSIONS: QGJY alleviates migraine and inhibits central sensitization in rats, potentially by downregulating P2X7R expression, concomitantly suppressing autophagy, attenuating microglial activation, and reducing pro-inflammatory cytokine release. (🧵 8/8)
A preprint using: B6;129S7-Prnptm (RRID:IMSR_EM:00056) from #InternationalMouseSt was published.
SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #reproducibility #RRID
SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #reproducibility #RRID
A brain-penetrant P2X7R antagonist mitigates Alzheimer’s disease pathology
www.biorxiv.org
April 15, 2026 at 12:00 PM
A preprint using: B6;129S7-Prnptm (RRID:IMSR_EM:00056) from #InternationalMouseSt was published.
SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #reproducibility #RRID
SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #reproducibility #RRID
This limitation, alongside heterogeneity in experimental designs, underscores the need for more translational research in humans. Nonetheless, given its central role, P2X7R inhibition emerges as a promising disease-modifying therapeutic strategy, (🧵 8/9)
May 21, 2026 at 10:43 AM
This limitation, alongside heterogeneity in experimental designs, underscores the need for more translational research in humans. Nonetheless, given its central role, P2X7R inhibition emerges as a promising disease-modifying therapeutic strategy, (🧵 8/9)
ATP-P2X7R axis is a key driver of pathological purinergic signaling, representing a largely unexplored but highly promising clinical target against a wide spectrum of kidney diseases according to a new "Mechanisms of Kidney Diseases" article in JASN. https://bit.ly/JASN0711
#ASNJASN
#ASNJASN
May 8, 2025 at 2:00 PM
ATP-P2X7R axis is a key driver of pathological purinergic signaling, representing a largely unexplored but highly promising clinical target against a wide spectrum of kidney diseases according to a new "Mechanisms of Kidney Diseases" article in JASN. https://bit.ly/JASN0711
#ASNJASN
#ASNJASN
Evidence indicates that P2X7R activation triggers a cascade of pro-inflammatory events, including Pannexin-1 (PANX1) channel opening, NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome assembly, and the (🧵 3/9)
May 21, 2026 at 10:43 AM
Evidence indicates that P2X7R activation triggers a cascade of pro-inflammatory events, including Pannexin-1 (PANX1) channel opening, NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome assembly, and the (🧵 3/9)
🚨 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭 🚨
💡Longitudinal P2X7R and Myelin PET Reveal Distinct Neuroinflammatory and White Matter Signatures Compared with TSPO PET and DTI-MRI in the TgF344-AD rat model
📄 NeuroImage
👉 https://doi.org/10.1016/j.neuroimage.2026.121753
💡Longitudinal P2X7R and Myelin PET Reveal Distinct Neuroinflammatory and White Matter Signatures Compared with TSPO PET and DTI-MRI in the TgF344-AD rat model
📄 NeuroImage
👉 https://doi.org/10.1016/j.neuroimage.2026.121753
February 16, 2026 at 9:10 AM
🚨 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭 🚨
💡Longitudinal P2X7R and Myelin PET Reveal Distinct Neuroinflammatory and White Matter Signatures Compared with TSPO PET and DTI-MRI in the TgF344-AD rat model
📄 NeuroImage
👉 https://doi.org/10.1016/j.neuroimage.2026.121753
💡Longitudinal P2X7R and Myelin PET Reveal Distinct Neuroinflammatory and White Matter Signatures Compared with TSPO PET and DTI-MRI in the TgF344-AD rat model
📄 NeuroImage
👉 https://doi.org/10.1016/j.neuroimage.2026.121753
mena like cortical spreading depression (CSD) and trigeminovascular activation. Consistently, pharmacological or genetic inhibition of P2X7R has been shown to attenuate CSD, pain behaviors, and associated cognitive deficits in animal models of migraine. (🧵 5/9)
May 21, 2026 at 10:43 AM
mena like cortical spreading depression (CSD) and trigeminovascular activation. Consistently, pharmacological or genetic inhibition of P2X7R has been shown to attenuate CSD, pain behaviors, and associated cognitive deficits in animal models of migraine. (🧵 5/9)
Although these findings position P2X7R as a master regulator of neuroinflammation in migraine by integrating glial activation, cytokine release, and neuronal sensitization, most supporting evidence currently derives from animal models, a crucial point to note. (🧵 7/9)
May 21, 2026 at 10:43 AM
Although these findings position P2X7R as a master regulator of neuroinflammation in migraine by integrating glial activation, cytokine release, and neuronal sensitization, most supporting evidence currently derives from animal models, a crucial point to note. (🧵 7/9)
Migraine, a disabling neurological disorder, is increasingly recognized as being driven by neuroinflammatory processes. Purinergic receptor P2X ligand-gated ion channel 7 (P2X7R), an ATP-gated ion channel highly expressed in microglia, astrocytes, and neurons, has emerged as a (🧵 1/9)
May 21, 2026 at 10:43 AM
Migraine, a disabling neurological disorder, is increasingly recognized as being driven by neuroinflammatory processes. Purinergic receptor P2X ligand-gated ion channel 7 (P2X7R), an ATP-gated ion channel highly expressed in microglia, astrocytes, and neurons, has emerged as a (🧵 1/9)
Resumindo, eles sugerem que a ativação exagerada do receptor celular chamado P2X7R está associada à tempestade inflamatória. Assim, inibir a expressão exagerada do P2X7 e também do complexo de proteínas inflamatórias poderiam ser estratégias para prevenir e tratar o problema.
March 18, 2021 at 9:21 PM
Resumindo, eles sugerem que a ativação exagerada do receptor celular chamado P2X7R está associada à tempestade inflamatória. Assim, inibir a expressão exagerada do P2X7 e também do complexo de proteínas inflamatórias poderiam ser estratégias para prevenir e tratar o problema.
Has anyone tried Ruscogenin to treat Sjogren's? I see all the indicators it should work: blocks #TLR4, #NLRP3, #MYD88, #NfKB, #P2X7R, #TNF-A and #IL-1B activation, and has been shown in mouse models to ameliorate #Sjogren's
pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov/articles/PMC...
Ruscogenin Ameliorated Sjögren's Syndrome by Inhibiting NLRP3 Inflammasome Activation
This article investigated the role and the specific mechanism of Ruscogenin in Sjögren's syndrome (SS). NOD/ShiLtJ mice were treated with Ruscogenin, and acinar cells isolated from submandibular gland...
pmc.ncbi.nlm.nih.gov
February 13, 2025 at 2:38 PM
Has anyone tried Ruscogenin to treat Sjogren's? I see all the indicators it should work: blocks #TLR4, #NLRP3, #MYD88, #NfKB, #P2X7R, #TNF-A and #IL-1B activation, and has been shown in mouse models to ameliorate #Sjogren's
pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov/articles/PMC...